Effects and levels of coenzyme Q10 in lung and liver in bleomycin-hamster model of lung fibrosis.
As part of an ongoing study to search for potential antifibrotic agents which may reduce bleomycin-induced fibrosis of lung, hamsters were treated with 25 mg/kg coenzyme Q10 (CoQ10) for 2 days prior to and daily for 14 days after intratracheal instillation of bleomycin (5 U/kg body wt.). CoQ10 was found not to attenuate bleomycin-induced lung fibrosis. Treatment with CoQ10 did not raise the lung and liver content of CoQ10. On the other hand, bleomycin treatment alone tended to increase the lung and liver content of CoQ10. At the higher dose (7.5 U/kg), bleomycin almost doubled the hepatic CoQ10 content. Treatment with the lower dose (5 U/kg) of bleomycin and CoQ10 was always associated with higher levels of CoQ10 in both liver and lungs than treatment with either of them alone.
Giri
S N
SN
Department of Veterinary Pharmacology and Toxicology, School of Veterinary Medicine, University of California, Davis 95616.
Graver
D F
DF
D000818:Animals; D001761:Bleomycin / Q000037:antagonists & inhibitors / Q000633:toxicity*; D002851:Chromatography, High Pressure Liquid; D006224:Cricetinae; D004305:Dose-Response Relationship, Drug; D006909:Hydroxyproline / Q000378:metabolism; D007274:Injections, Intraperitoneal; D008099:Liver / Q000187:drug effects* / Q000378:metabolism; D008168:Lung / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D008647:Mesocricetus; D009929:Organ Size; D011658:Pulmonary Fibrosis / Q000139:chemically induced / Q000378:metabolism; D014451:Ubiquinone / Q000378:metabolism / Q000627:therapeutic use*
D001761:Bleomycin; D014451:Ubiquinone; C025204:Ubiquinone Q2; D006909:Hydroxyproline